C15:0 Pentadecanoic Acid: The Odd-Chain Fatty Acid Marketed as the First Essential Nutrient in 90 Years

Pentadecanoic acid (C15:0) is a saturated odd-chain fatty acid found at low levels in dairy fat, certain fish, and plant sources. Its sudden prominence in supplement marketing stems from a 2020 series of papers by Stephanie Venn-Watson and colleagues arguing that C15:0 should be reclassified as an essential nutrient, paired with launch of a commercial product. The observational and mechanistic data are interesting; the "essential nutrient" framing is contested and has not been accepted by major nutrition authorities.

The Venn-Watson hypothesis

Venn-Watson and colleagues 2020 reported that low serum C15:0 in bottlenose dolphins was associated with a syndrome of inflammation, anemia, and metabolic dysfunction resembling human metabolic disease. The investigators then surveyed human cohort data and reported that low serum C15:0 was associated with higher all-cause mortality, type 2 diabetes, cardiovascular disease, and nonalcoholic fatty liver disease across multiple prospective cohorts [1]. The proposed mechanism is that C15:0 stabilizes red cell membranes, activates AMPK and PPAR signaling, and reduces ferroptotic cell death [2].

What the prospective cohort evidence actually shows

The Forouhi and colleagues 2014 analysis of the EPIC-InterAct cohort found that higher plasma C15:0 and C17:0 (both odd-chain saturated fatty acids derived largely from dairy fat) were associated with a 17 to 19 percent lower risk of incident type 2 diabetes [3]. Similar findings have been reported in PREDIMED, ARIC, and Nurses' Health Study cohorts. The biomarker is a reasonable marker of dairy fat intake, and most authorities interpret the association as reflecting dairy or fermented dairy consumption patterns rather than a direct C15:0 effect. Mendelian randomization studies attempting to isolate causal effects of dairy biomarkers have been inconclusive.

The "first essential nutrient in 90 years" framing

Establishing essentiality of a nutrient requires demonstration that dietary deficiency produces a reproducible deficiency syndrome that is reversed by supplementation. C15:0 deficiency in humans has not been demonstrated to produce a reproducible clinical syndrome — the case rests on cross-sectional and prospective associations, not deficiency-repletion experiments. Major nutrition bodies (NAS Dietary Reference Intakes, EFSA Panel on Dietetic Products) have not adopted C15:0 as an essential nutrient. The marketing language "first essential nutrient since 1928" (when omega-3 essentiality was proposed) is contested.

Supplement form: what is being sold

The commercial product (Fatty15) provides 100 mg per day of free C15:0 fatty acid in vegetable oil. A single tablespoon of butter contains roughly 30 to 50 mg of C15:0; an 8-ounce serving of whole milk contains about 20 to 30 mg. The supplement dose is therefore meaningfully higher than typical dietary exposure for low-dairy consumers but not dramatically higher than for regular dairy consumers. Limited proprietary trials in adults have reported reductions in liver enzymes and CRP markers, but independent replication is awaited [4].

Plausibility and the honest summary

C15:0 has a mechanistic story, supportive but indirect epidemiology, and limited proprietary clinical trial evidence. It is biologically plausible that supplementation alters metabolism beneficially in a subset of low-dairy consumers. Whether this rises to the level of meaningful clinical benefit for metabolic disease or longevity is not yet established. Patients interested in the underlying nutrition question can achieve similar serum C15:0 with regular consumption of whole-fat fermented dairy (yogurt, kefir, cheese), which also delivers calcium, K2, and conjugated linoleic acid. The supplement industry framing has run substantially ahead of the regulatory and nutrition-science consensus.